false
0001446847
0001446847
2025-08-29
2025-08-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 29, 2025
IRONWOOD PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
| Delaware |
|
001-34620 |
|
04-3404176 |
| |
|
|
|
|
| (State
or other jurisdiction |
|
|
|
(I.R.S.
Employer |
| of incorporation) |
|
(Commission
File Number) | |
Identification Number) |
| 100 Summer Street, Suite 2300 |
|
|
|
|
| Boston, Massachusetts |
|
|
|
02110 |
| |
|
|
|
|
| (Address of principal |
|
|
|
|
| executive offices) |
|
|
|
(Zip code) |
(617)
621-7722
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
| Class A common stock, $0.001 par value |
IRWD |
Nasdaq Global Select Market |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events.
On August 29, 2025, Ironwood
Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market
LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq
Listing Rule 5450(a)(1) (the “Bid Price Rule”) for continued inclusion on the Nasdaq Global Select Market. As previously disclosed
in the Company’s Current Report on Form 8-K filed on June 3, 2025, the Company received a written notice from Nasdaq on May 28,
2025, notifying the Company that it was not in compliance with the Bid Price Rule because its Class A common stock,
par value $0.001 per share (the “Common Stock”) had failed to meet the $1.00 per share minimum bid price requirement
for continued inclusion on the Nasdaq Global Select Market. To regain compliance with the Bid Price Rule, the Company’s Common Stock
was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days. This requirement was
met, and the matter is now closed.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Ironwood Pharmaceuticals, Inc. |
| |
|
|
| Dated: September 3, 2025 |
By: |
/s/ Gregory Martini |
| |
|
Name: |
Gregory Martini |
| |
|
Title: |
Senior Vice President, Chief Financial Officer |
